[1] [3] Key safety considerations include: Bleeding risk assessment : Ensure patients understand signs of bleeding (unusual bruising, blood in urine or stools, prolonged bleeding from cuts) and when to seek help Medication adherence : Address any gastrointestinal side effects promptly to prevent non-adherence to either medication Hydration status : Gastrointestinal adverse effects may cause dehydration, which can affect renal function and potentially impact DOAC clearance or increase risk of acute kidney injury Injection site management : Patients should rotate Ozempic injection sites and avoid injecting into areas with bruising or active bleeding Pancreatitis awareness : Stop Ozempic and seek urgent medical attention if severe persistent abdominal pain radiating to the back occurs Diabetic retinopathy monitoring : Particularly important in patients with pre-existing retinopathy Hypoglycaemia risk : Increased when Ozempic is used with insulin or sulfonylureas Patient education is paramount
Quick Answer: A microdose of GLP-1 is an informal term for using GLP-1 receptor agonist medications at doses substantially lower than those licensed by UK regulatory authorities, an approach that is not evidence-based or recommended
33 In a phase 2 open-label study, NGM282 improved the histological features of MASH within 12 weeks, demonstrating significant reductions in NAS and fibrosis scores, along with improvements in noninvasive imaging and serum markers
The current report discusses the mechanism of action, classification, pharmacokinetic and pharmacodynamic properties of various GLP-1 RAs
And the early data suggests that difference matters
